Ligand Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LGND and other ETFs, options, and stocks.

About LGND

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. 

CEO
Todd Christopher Davis
CEOTodd Christopher Davis
Employees
68
Employees68
Headquarters
Jupiter, Florida
HeadquartersJupiter, Florida
Founded
1987
Founded1987
Employees
68
Employees68

LGND Key Statistics

Market cap
3.91B
Market cap3.91B
Price-Earnings ratio
92.72
Price-Earnings ratio92.72
Dividend yield
Dividend yield
Average volume
232.10K
Average volume232.10K
High today
$199.39
High today$199.39
Low today
$194.00
Low today$194.00
Open price
$195.03
Open price$195.03
Volume
181.11K
Volume181.11K
52 Week high
$212.49
52 Week high$212.49
52 Week low
$93.58
52 Week low$93.58

Stock Snapshot

With a market cap of 3.91B, Ligand Pharmaceuticals(LGND) trades at $198.43. The stock has a price-to-earnings ratio of 92.72.

During the trading session on 2025-12-18, Ligand Pharmaceuticals(LGND) shares reached a daily high of $199.39 and a low of $194.00. At a current price of $198.43, the stock is +2.3% higher than the low and still -0.5% under the high.

Trading volume for Ligand Pharmaceuticals(LGND) stock has reached 181.11K, versus its average volume of 232.1K.

Over the past 52 weeks, Ligand Pharmaceuticals(LGND) stock has traded between a high of $212.49 and a low of $93.58.

Over the past 52 weeks, Ligand Pharmaceuticals(LGND) stock has traded between a high of $212.49 and a low of $93.58.

LGND News

Simply Wall St 13h
Ligand Pharmaceuticals Valuation After Its 2026 Royalty-Focused Earnings Outlook Drives Investor Interest

Ligand Pharmaceuticals (LGND) just put numbers around its 2026 outlook, projecting total revenue between $245 million and $285 million, with the bulk expected f...

Ligand Pharmaceuticals Valuation After Its 2026 Royalty-Focused Earnings Outlook Drives Investor Interest
TipRanks 2d
CFO Makes Significant Move with Ligand Pharma Stock Sale

New insider activity at Ligand Pharma ( (LGND) ) has taken place on December 16, 2025. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fu...

TipRanks 3d
Promising Developments and Revenue Prospects Reinforce Buy Rating for Ligand Pharma

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma and keeping the price target at $231.00. Claim 50% Off TipRanks Premium a...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own LGND. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.